Biotronik has begun enrolling patients for a clinical study assessing the performance of its newest coronary stent.
The BIOVITESSE stent trial will assess the safety and clinical performance of the device in the treatment of de novo coronary artery lesions, with the first patient having been enrolled in Switzerland.
“Biotronik has commenced patient enrolment for a new study assessing the benefits of a new stent in treating de novo coronary artery lesions.“
To run in five centres in Switzerland until August 2019, the trial will target primary endpoints including strut coverage at one month and in-stent late lumen loss at nine months, to be assessed via optical coherence tomography and quantitative coronary angiography.
Biotronik's new polymer-free coronary stent combines the features of the proven PRO-Kinetic Energy stent with a new anti-proliferative limus drug designed to prevent excessive cell growth.
Dr Daniel Buehler, Biotronik's president for vascular intervention, said: "Our Biovitesse stent systems ease of use reflects our long-term expertise in developing coronary stents, which allows us to continue to improve performance and provide enhanced treatment options."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices